Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6800-3. doi: 10.1016/j.bmcl.2011.09.036. Epub 2011 Sep 18.

Continued exploration of biphenylsulfonamide scaffold as a platform for aggrecanase-1 inhibition.

Author information

1
Worldwide Medicinal Chemistry, Pfizer Global Research and Development, 200 CambridgePark Drive, Cambridge, MA 02140, USA.

Abstract

Design, synthesis and structure-activity relationship of a series of biphenylsulfonamido-3-methylbutanoic acid based aggrecanase-1 inhibitors are described. In addition to robust aggrecanase-1 inhibition, these compounds also exhibit potent MMP-13 activity. In cell-based cartilage explants assay compound 48 produced 87% inhibition of proteoglycan degradation at 10 μg/mL. Good pharmacokinetic properties were demonstrated by 46 with a half-life of 6h and bioavailability of 23%.

PMID:
21982494
DOI:
10.1016/j.bmcl.2011.09.036
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center